Inactive Instrument

Highlights Oramed Pharmaceuticals, Inc. Xetra

Equities

OJU

US68403P1049

End-of-day quote Xetra Other stock markets
- ^EUR	-

Jun. 26	Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program	MT
Jun. 26	Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program	Jun. 26	MT
Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares.	Jun. 26	CI
Oramed Pharmaceuticals Inc. authorizes a Buyback Plan.	Jun. 25	CI
Scilex Holding Signs Commitment Letter for $100 Million Financing; Shares Advance Premarket	Jun. 12	MT
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	23-09-21	MT
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	23-09-20	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Oramed Pharmaceuticals Inc. entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.	23-08-06	CI
Oramed Pharmaceuticals, Hefei Tianhui Biotech Sign Non-Binding Agreement to Form Joint Venture	23-08-02	MT
Oramed Pharmaceuticals Inc. Signs Term Sheet with Hefei Tianhui Biotech Co., Ltd. to Create Joint Venture to Advance Oral Drug Delivery Technology Globally	23-08-02	CI
Oramed Pharmaceuticals Inc. Announces its Chinese Partner, Hefei Tianhui Biotechnology Co. Ltd. Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China	23-05-15	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes	23-01-11	CI
Oramed Pharmaceuticals Secures US Patent for Diabetes Combination Therapy	23-01-04	MT
Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes	23-01-04	CI
Oramed Pharmaceuticals Reports Additional Positive Mid-Stage Data for Oral Insulin Candidate	22-11-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oramed Pharmaceuticals, Inc. Xetra

Equities

OJU

US68403P1049

Highlights

Filters